SLC6A3 Membrane Protein Introduction

Introduction of SLC6A3

SLC6A3 is encoded by SLC6A3 gene. It belongs to the solute carrier family 6 which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. It is a norepinephrine transporter which can remove norepinephrine from synaptic cleft to cytosol, and is responsible for the regulation of the rewarding and motivational processes underlying food intake and eating behaviors. Meanwhile, many studies conducted on SLC6A3 show that it is related with various diseases, such as idiopathic epilepsy, attention-deficit hyperactivity disorder and tobacco addiction.

Basic Information of SLC6A3
Protein Name	Sodium-dependent dopamine transporter
Gene Name	SLC6A3
Aliases	DAT1
Organism	Homo sapiens (Human)
UniProt ID	Q01959
Transmembrane Times	12
Length (aa)	620
Sequence	MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDRETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELALGQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQLTACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSVDFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGIDSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAAGTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSIVTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKDRELVDRGEVRQFTLRHWLKV

Function of SLC6A3 Membrane Protein

SLC6A3, also named as dopamine transporter (DAT), is mainly expressed in the striatum. The SLC6A3 gene codes for a presynaptic transporter for uptake of dopamine, and thus affecting the amount of available dopamine in the synaptic cleft. Recent studies indicate that SLC6A3 variants are strongly associated with obesity features, metabolic profiles, and dietary intake. In addition, researches have confirmed several SLC6A3 SNPs could be potential therapeutic targets with the value in the early diagnosis and management of neurodevelopmental diseases in newborns.

Fig.1 Structure of SLC6A3 membrane protein.

Application of SLC6A3 Membrane Protein in Literature

González-Giraldo Y., et al. Two dopaminergic genes, DRD4 and SLC6A3, are associated with body mass index in a Colombian sample of young adults. Arch Physiol Biochem. 2017, 16:1-5. PubMed ID: 29145734

This article reports the association between the SLC6A3, DRD4 polymorphisms and body mass index in 232 Colombian young subjects. These results indicate that a significant association is found in these two genes and BMI in healthy young adults.
Ludmer J.A., et al. Maternal DRD2, SLC6A3, and OXTR genotypes as potential moderators of the relation between maternal history of care and maternal cortisol secretion in the context of mother-infant separation. Biol Psychol. 2017, 129:154-164. PubMed ID: 28890000

This article analyzes the relationship between DRD2, SLC6A3, and OXTR and cortisol secretion in anticipation of infant stress. These results indicate that DRD2, SLC6A3, and OXTR genetic characteristics are related to the maternal protective system and anticipatory cortisol secretion.
Arpón A., et al. Methylation changes and pathways affected in preterm birth: a role for SLC6A3 in neurodevelopment. Epigenomics. 2018, 10(1):91-103. PubMed ID: 29172706

Authors in this group analyze the expression and methylation levels of SLC6A3 in white blood cells of full-term newborns. The data show that highly methylation of SLC6A3 gene is one of risk factors for attention-deficit/hyperactivity disorder.
Soleimani R., et al. SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2018, 177(3):287-300. PubMed ID: 29171685

This article conducts a meta-analyse to identify the association between SLC6A3 gene polymorphisms and methylphenidate in children with attention-deficit hyperactivity disorder (ADHD). The results suggest that SLC6A3 variants are strongly associated with severity of ADHD.
Kurian M.A., et al. SLC6A3-related dopamine transporter deficiency syndrome. Gene Reviews. 2017. PubMed ID: 28749637

This article conducts a case-control study to detect the expression of SLC6A3 and the gene polymorphisms in patients who suffer from dopamine transporter deficiency syndrome. The data illustrate that SLC6A3 variants are associated with the risk of DTDS.

SLC6A3 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC6A3 antibody development services.

As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: